Consolidated Statements of Cash Flows (USD $)	6 Months Ended		166 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013
Cash flows from operating activities:
Net loss	$ (1,065,433)	$ (1,844,982)	$ (39,987,047)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,598	216	24,291
Gain on sale of furniture and equipment	0	0	(2,200)
Stock based compensation and consulting	11,730	107,585	2,774,391
Common stock issued for services rendered	3,850	88,053	530,963
Common stock issued in debt issuance cost	0	0	177,086
Notes payable issued for intangibles expensed as research and development	0	0	150,000
Note payable issued for interest	0	0	1,000
Convertible note issued for services rendered	0	0	2,700
Warrants issued for services	89,850	0	773,220
Warrants issued for debt issuance cost	0	0	1,782,828
Warrants issued for early warrant exercise incentive	0	0	2,727,103
Units issued for interest	0	0	8,700
Units issued for debt extinguisment	0	0	870,981
Amortization of original issue discount on debt	0	7,241	2,675,348
Amortization of debt issuance costs	293,829	344,940	4,129,847
Bargain conversion option added to note payable- related party for debt extinguishment	0	0	48,214
Write-off debt issuance cost for debt extinguishment	0	0	42,797
Write-off of deferred offering cost	0	0	59,696
License rights expensed as research and development, paid by issuance of common stock to CS Medical Technologies, LLC	0	0	475,000
License rights expensed as research and development, paid by issuance of common stock to Profile, LLC	0	0	1,713,600
Changes in operating assets and liabilities:
Prepaid expenses	31,393	(54,151)	(44,748)
Accounts payable	35,205	29,945	3,641,373
Accrued expenses	302,705	806,266	1,542,633
Net cash used in operating activities	(295,273)	(514,887)	(15,882,224)
Cash flows from investing activities:
Purchases of equipment and furniture	0	0	(46,325)
Deposit into a restricted cash account	(50,000)	0	(94,214)
Withdrawal from a restricted cash account	0	0	44,214
Net cash used in investing activities	(50,000)	0	(96,325)
Cash flows from financing activities:
Proceeds of note payable, bank	0	0	700,000
Payments of note payable, bank	(50,000)	(200,000)	(1,750,000)
Proceeds of notes payable	99,312	145,628	1,319,412
Payment of notes payable	(33,266)	(41,527)	(1,813,888)
Proceeds of notes payable - related party	0	0	1,346,596
Payments of notes payable - related party	0	0	(289,300)
Proceeds from long-term convertible notes payable and bank debt	0	0	4,357,362
Proceeds from long-term convertible notes payable - related party	0	200,000	1,913,500
Payments on convertible debt	(2,500)	0	(2,500)
Payments on long-term bank debt	0	0	(600,000)
Net proceeds from warrants	0	0	104,500
Proceeds from exercise of warrants	0	0	2,406,788
Payments for debt issuance costs	(2,500)	0	(798,227)
Payment for rescission of common stock	0	0	(100,000)
Payments for offering expenses	0	0	(651,962)
Cost of reverse merger	0	0	(162,556)
Advances from related parties	216,341	0	216,341
Proceeds from debt subscription agreement	50,000	0	50,000
Net proceeds from issuance of common stock	0	432,000	9,737,756
Net cash provided by financing activities	277,387	536,101	15,983,822
Net increase (decrease) in cash	(67,886)	21,214	5,273
Cash, beginning of the period	73,159	25,843	0
Cash, end of the period	$ 5,273	$ 47,057	$ 5,273